Affimed to Present at Upcoming Investor Conferences
August 26 2021 - 6:30AM
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that management will present and host
one-on-one meetings at the following investor conferences during
the month of September 2021.
Citi’s 16th Annual BioPharma Virtual Conference
(September 8-10, 2021)Date: Wednesday, September 8, 2021No
presentation, only one-on-one meetings Location: Virtual
2021 Wells Fargo Virtual Healthcare Conference
(September 9-10, 2021)Date: Thursday, September 9,
2021Presentation Time: 8:00 a.m. Eastern
TimeWebcast: https://www.affimed.com/investors/webcasts_cp/Location:
Virtual
Morgan Stanley 19th
Annual Global Healthcare Conference (September 9-15,
2021)Date: Friday, September 10, 2021No Presentation, only
one-on-one meetings Location: Virtual
Cantor Fitzgerald Virtual Global Healthcare Conference
2021 (September 27-30, 2021)Date: Monday, September 27,
2021Presentation Time: 10:00 a.m. Eastern
TimeWebcast: https://www.affimed.com/investors/webcasts_cp/Location:
Virtual
For more information or to schedule a one-on-one meeting with
Affimed’s management, please contact your conference representative
or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at
+1 (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer by actualizing the untapped potential of the innate
immune system. The company’s proprietary ROCK® platform enables a
tumor-targeted approach to recognize and kill a range of
hematologic and solid tumors, enabling a broad pipeline of
wholly-owned and partnered single agent and combination therapy
programs. The ROCK® platform predictably generates customized
innate cell engager (ICE®) molecules, which use patients’ immune
cells to destroy tumor cells. This innovative approach enabled
Affimed to become the first company with a clinical-stage ICE®.
Headquartered in Heidelberg, Germany, with offices in New York, NY,
Affimed is led by an experienced team of biotechnology and
pharmaceutical leaders united by a bold vision to stop cancer from
ever derailing patients’ lives. For more about the company’s
people, pipeline and partners, please visit: www.affimed.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, the potential of AFM13, AFM24, and
our other product candidates, the value of our ROCK® platform, our
ongoing and planned preclinical development and clinical trials,
our collaborations and development of our products in combination
with other therapies, the timing of and our ability to make
regulatory filings and obtain and maintain regulatory approvals for
our product candidates, our intellectual property position, our
collaboration activities, our ability to develop commercial
functions, clinical trial data, our results of operations, cash
needs, financial condition, liquidity, prospects, future
transactions, growth and strategies, the industry in which we
operate, the trends that may affect the industry or us, impacts of
the COVID-19 pandemic, the benefits to Affimed of orphan drug
designation and the risks, uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the SEC. Given these risks, uncertainties, and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the
future.
Investor Relations ContactAlexander
FudukidisDirector, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024